Neuroventi

Developer of drugs to treat autistic spectrum disorders and attention deficit hyperactivity disorder

placeSeoul, Seoul, South Korea calendar_todayFounded 2015 language neuroventi.com

Innovation

19 patent families (3 granted) — focus: Human necessities, Chemistry & metallurgy; filing pace steady. Cited 131 times.

YearFilings
20171
20197
20204
20215
20222
20234
20244
20256

Investor mix

2 investors on record; lead investors include HLB.

Investor typeCountShare
Venture capital150%
Other / undisclosed150%
Coming soon